Friedman R, Caflisch A. Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring. ChemMedChem. 2009; 4:1317–26.

Article
CAS
PubMed
Google Scholar

Kubinyi H. Qsar and 3d qsar in drug design part 1: methodology. Drug Discov Today. 1997; 2(11):457–67.

Article
CAS
Google Scholar

Kubinyi H. Qsar and 3d qsar in drug design part 2: applications and problems. Drug Discov Today. 1997; 2(12):538–46.

Article
CAS
Google Scholar

Alvarsson J, Lampa S, Schaal W, Andersson C, Wikberg JE, Spjuth O. Large-scale ligand-based predictive modelling using support vector machines. J Cheminform. 2016; 8:39.

Article
PubMed
PubMed Central
Google Scholar

Lampa S, Alvarsson J, Spjuth O. Towards agile large-scale predictive modelling in drug discovery with flow-based programming design principles. J Cheminform. 2016; 8:67.

Article
PubMed
PubMed Central
Google Scholar

van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise?. Nat Rev Drug Discov. 2003; 2(3):192–204.

CAS
PubMed
Google Scholar

Datta S, Grant DJ. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov. 2004; 3(1):42–57.

Article
CAS
PubMed
Google Scholar

Brown ED, Wright GD. Antibacterial drug discovery in the resistance era. Nature. 2016; 529(7586):336–43.

Article
CAS
PubMed
Google Scholar

Gjini E, Brito PH. Integrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs Adaptive Treatment. PLoS Comput Biol. 2016; 12(4):1004857.

Article
Google Scholar

Friedman R. Drug resistance missense mutations in cancer are subject to evolutionary constraints. PLoS ONE. 2013; 8(12):82059.

Article
Google Scholar

Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650–65.

Article
CAS
PubMed
Google Scholar

Grafone T, Palmisano M, Nicci C, Storti S. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012; 6(1):8.

Article
Google Scholar

Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004; 4(5):361–70.

Article
CAS
PubMed
Google Scholar

Lopez S, Voisset E, Tisserand JC, Mosca C, Prebet T, Santamaria D, Dubreuil P, De Sepulveda P. An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. Oncotarget. 2016; 7(32):51163–73.

Article
PubMed
PubMed Central
Google Scholar

Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007; 12(6):501–13.

Article
CAS
PubMed
Google Scholar

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001; 97(8):2434–9.

Article
CAS
PubMed
Google Scholar

Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. 2008; 111(3):1552–9.

Article
CAS
PubMed
PubMed Central
Google Scholar

Matsuno N, Nanri T, Kawakita T, Mitsuya H, Asou N. A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia. Leukemia. 2005; 19(3):480–1.

Article
CAS
PubMed
Google Scholar

Kindler T, Breitenbuecher F, Kasper S, Estey E, Giles F, Feldman E, Ehninger G, Schiller G, Klimek V, Nimer SD, Gratwohl A, Choudhary CR, Mueller-Tidow C, Serve H, Gschaidmeier H, Cohen PS, Huber C, Fischer T. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood. 2005; 105(1):335–40.

Article
CAS
PubMed
Google Scholar

Friedman R. Drug resistance in cancer: molecular evolution and compensatory proliferation. Oncotarget. 2016; 7(11):11746–55.

Article
PubMed
PubMed Central
Google Scholar

Gallogly MM, Lazarus HM. Midostaurin: an emerging treatment for acute myeloid leukemia patients. J Blood Med. 2016; 7:73–83.

CAS
PubMed
PubMed Central
Google Scholar

Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C, Serve H, Roesel J, Giles F, Feldman E, Ehninger G, Schiller GJ, Nimer S, Stone RM, Wang Y, Kindler T, Cohen PS, Huber C, Fischer T. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood. 2006; 107(1):293–300.

Article
CAS
PubMed
Google Scholar

Williams AB, Nguyen B, Li L, Brown P, Levis M, Leahy D, Small D. Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors. Leukemia. 2013; 27(1):48–55.

Article
CAS
PubMed
Google Scholar

Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń LM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015; 525(7570):543–7.

Article
CAS
PubMed
PubMed Central
Google Scholar

Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, Giotopoulos G, Lugo D, Jeffrey P, Lee SC, Carpenter C, Gregory R, Ramsay RG, Lane SW, Abdel-Wahab O, Kouzarides T, Johnstone RW, Dawson SJ, Huntly BJ, Prinjha RK, Papenfuss AT, Dawson MA. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015; 525(7570):538–42.

Article
CAS
PubMed
Google Scholar

Rottapel R, Turck CW, Casteran N, Liu X, Birnbaum D, Pawson T, Dubreuil P. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. Oncogene. 1994; 9(6):1755–65.

CAS
PubMed
Google Scholar

Dosil M, Wang S, Lemischka IR. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 1993; 13(10):6572–85.

Article
CAS
PubMed
PubMed Central
Google Scholar

Marchetto S, Fournier E, Beslu N, Aurran-Schleinitz T, Dubreuil P, Borg JP, Birnbaum D, Rosnet O. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia. 1999; 13(9):1374–82.

Article
CAS
PubMed
Google Scholar

Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol. 1999; 65(3):372–80.

Article
CAS
PubMed
Google Scholar

Zhang S, Broxmeyer HE. p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochem Biophys Res Commun. 1999; 254(2):440–5.

Article
CAS
PubMed
Google Scholar

Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia. 2002; 16(2):244–53.

Article
CAS
PubMed
Google Scholar

Martelli AM, Evangelisti C, Chiarini F, McCubrey JA. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget. 2010; 1(2):89–103.

PubMed
PubMed Central
Google Scholar

Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML, New agents and new directions. Oncotarget. 2011; 2(6):510–7.

Article
PubMed
PubMed Central
Google Scholar

Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008; 9(10):747–58.

Article
CAS
PubMed
Google Scholar

Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, Frohling S, Sexl V. Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016; 127(23):2890–2902.

Article
CAS
PubMed
PubMed Central
Google Scholar

Hirade T, Abe M, Onishi C, Taketani T, Yamaguchi S, Fukuda S. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells. Int J Hematol. 2016; 103(1):95–106.

Article
CAS
PubMed
Google Scholar

Park IK, Mundy-Bosse B, Whitman SP, Zhang X, Warner SL, Bearss DJ, Blum W, Marcucci G, Caligiuri MA. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015; 29(12):2382–9.

Article
CAS
PubMed
Google Scholar

Buetti-Dinh A, Pivkin IV, Friedman R. S100A4 and its role in metastasis – computational integration of data on biological networks. Mol Biosyst. 2015; 11(8):2238–46.

Article
CAS
PubMed
Google Scholar

Buetti-Dinh A, Pivkin IV, Friedman R. S100A4 and its role in metastasis – simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases. Mol Biosyst. 2015; 11(8):2247–54.

Article
CAS
PubMed
Google Scholar

Buetti-Dinh A, O’Hare T, Friedman R. Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy. PLoS ONE. 2016; 11(9):0163011.

Article
Google Scholar

Karlebach G, Shamir R. Modelling and analysis of gene regulatory networks. Nat Rev Mol Cell Biol. 2008; 9(10):770–80.

Article
CAS
PubMed
Google Scholar

Fisher J, Henzinger TA. Executable cell biology. Nat Biotechnol. 2007; 25(11):1239–49.

Article
CAS
PubMed
Google Scholar

Tigges M, Marquez-Lago TT, Stelling J, Fussenegger M. A tunable synthetic mammalian oscillator. Nature. 2009; 457(7227):309–12.

Article
CAS
PubMed
Google Scholar

Zavala E, Marquez-Lago TT. Delays induce novel stochastic effects in negative feedback gene circuits. Biophys J. 2014; 106(2):467–78.

Article
CAS
PubMed
PubMed Central
Google Scholar

Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R, Grantcharova V, Kohli N, West KA, Leszczyniecka M, Feldhaus MJ, Kudla AJ, Nielsen UB. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal. 2009; 2(77):31.

Article
Google Scholar

Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, Sorger PK. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol. 2009; 5:239.

PubMed
PubMed Central
Google Scholar

Kirouac DC, Schaefer G, Chan J, Merchant M, Orr C, Huang SA, Moffat J, Liu L, Gadkar K, Ramanujan S. Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model. NPJ Syst Biol Appl. 2017; 3:14.

Article
PubMed
PubMed Central
Google Scholar

Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal. 2013; 6(288):68.

Article
Google Scholar

Feiglin A, Hacohen A, Sarusi A, Fisher J, Unger R, Ofran Y. Static network structure can be used to model the phenotypic effects of perturbations in regulatory networks. Bioinformatics. 2012; 28(21):2811–8.

Article
CAS
PubMed
Google Scholar

Ruths D, Muller M, Tseng JT, Nakhleh L, Ram PT. The signaling petri net-based simulator: a non-parametric strategy for characterizing the dynamics of cell-specific signaling networks. PLoS Comput Biol. 2008; 4(2):1000005.

Article
Google Scholar

Silverbush D, Grosskurth S, Wang D, Powell F, Gottgens B, Dry J, Fisher J. Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia. Cancer Res. 2017; 77(4):827–38.

Article
CAS
PubMed
Google Scholar

Hall BA, Piterman N, Hajnal A, Fisher J. Emergent stem cell homeostasis in the C, elegans germline is revealed by hybrid modeling. Biophys J. 2015; 109(2):428–38.

Article
CAS
PubMed
PubMed Central
Google Scholar

Foo J, Liu LL, Leder K, Riester M, Iwasa Y, Lengauer C, Michor F. An Evolutionary Approach for Identifying Driver Mutations in Colorectal Cancer. PLoS Comput Biol. 2015; 11(9):1004350.

Article
Google Scholar

Foo J, Michor F. Evolution of acquired resistance to anti-cancer therapy. J Theor Biol. 2014; 355:10–20.

Article
PubMed
Google Scholar

Mumenthaler SM, Foo J, Leder K, Choi NC, Agus DB, Pao W, Mallick P, Michor F. Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Mol Pharm. 2011; 8(6):2069–79.

Article
CAS
PubMed
PubMed Central
Google Scholar

Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546–58.

Article
CAS
PubMed
PubMed Central
Google Scholar

Kreso A, O’Brien CA, van Galen P, Gan OI, Notta F, Brown AM, Ng K, Ma J, Wienholds E, Dunant C, Pollett A, Gallinger S, McPherson J, Mullighan CG, Shibata D, Dick JE. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science. 2013; 339(6119):543–8.

Article
CAS
PubMed
Google Scholar

Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4):633–44.

Article
CAS
PubMed
Google Scholar

de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan AJ, Gronroos E, Muhammad MA, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, Van Loo P, Rassl DM, Rintoul RC, Janes SM, Lee SM, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins TT, Lee CC, Tom W, Teefe E, Chen SC, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, Swanton C. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014; 346(6206):251–6.

Article
CAS
PubMed
PubMed Central
Google Scholar

Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346(6206):256–9.

Article
CAS
PubMed
PubMed Central
Google Scholar

Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform. 2015; 14(Suppl 4):19–31.

CAS
PubMed
PubMed Central
Google Scholar

Wodarz D, Komarova N. Can loss of apoptosis protect against cancer?. Trends Genet. 2007; 23(5):232–7.

Article
CAS
PubMed
Google Scholar

Meyer C, Drexler HG. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines. Leuk Lymphoma. 1999; 32(5-6):577–81.

Article
CAS
PubMed
Google Scholar

Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004; 103(1):267–74.

Article
CAS
PubMed
Google Scholar

Poh AR, O’Donoghue RJ, Ernst M. Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget. 2015; 6(18):15752–71.

Article
PubMed
PubMed Central
Google Scholar

Saito Y, Yuki H, Kuratani M, Hashizume Y, Takagi S, Honma T, Tanaka A, Shirouzu M, Mikuni J, Handa N, Ogahara I, Sone A, Najima Y, Tomabechi Y, Wakiyama M, Uchida N, Tomizawa-Murasawa M, Kaneko A, Tanaka S, Suzuki N, Kajita H, Aoki Y, Ohara O, Shultz LD, Fukami T, Goto T, Taniguchi S, Yokoyama S, Ishikawa F. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med. 2013; 5(181):181–52.

Article
Google Scholar

Poh AR, Love CG, Masson F, Preaudet A, Tsui C, Whitehead L, Monard S, Khakham Y, Burstroem L, Lessene G, Sieber O, Lowell C, Putoczki TL, O’Donoghue RJJ, Ernst M. Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression. Cancer Cell. 2017; 31(4):563–75.

Article
CAS
PubMed
PubMed Central
Google Scholar

O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016; 13(7):417–30.

Article
PubMed
Google Scholar

Placke T, Faber K, Nonami A, Putwain SL, Salih HR, Heidel FH, Kramer A, Root DE, Barbie DA, Krivtsov AV, Armstrong SA, Hahn WC, Huntly BJ, Sykes SM, Milsom MD, Scholl C, Frohling S. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014; 124(1):13–23.

Article
CAS
PubMed
PubMed Central
Google Scholar

Hernandez Maganhi S, Jensen P, Caracelli I, Zukerman Schpector J, Frohling S, Friedman R. Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein. Protein Sci. 2017; 26(4):870–9.

Article
CAS
PubMed
PubMed Central
Google Scholar

Leung AY, Man CH, Kwong YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia. 2013; 27(2):260–8.

Article
CAS
PubMed
Google Scholar

Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood. 2008; 111(7):3723–34.

Article
CAS
PubMed
PubMed Central
Google Scholar

Agrawal V, Kishan KV. Promiscuous binding nature of SH3 domains to their target proteins. Protein Pept Lett. 2002; 9(3):185–93.

Article
CAS
PubMed
Google Scholar

Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortes J, Elliott R, Pancholi S, Baselga J, Dowsett M, Martin LA, Turner NC, Serra V. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. Cancer Res. 2016; 76(8):2301–13.

Article
CAS
PubMed
PubMed Central
Google Scholar

Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 2016; 6(4):353–67.

Article
CAS
PubMed
Google Scholar

Milo R, Jorgensen P, Moran U, Weber G, Springer M. BioNumbers–the database of key numbers in molecular and cell biology. Nucleic Acids Res. 2010; 38(Database issue):750–3.

Article
Google Scholar

Hill AV. The possible effect of the aggregation of the molecules of haemoglobin on its dissociation curves. J Physiol. 1910; 40:4–7.

Google Scholar

Cheng Z, Liu F, Zhang XP, Wang W. Robustness analysis of cellular memory in an autoactivating positive feedback system. FEBS Lett. 2008; 582(27):3776–82.

Article
CAS
PubMed
Google Scholar

Song H, Smolen P, Av-Ron E, Baxter DA, Byrne JH. Dynamics of a minimal model of interlocked positive and negative feedback loops of transcriptional regulation by cAMP-response element binding proteins. Biophys J. 2007; 92(10):3407–24.

Article
CAS
PubMed
PubMed Central
Google Scholar

Galassi M, Davies J, Theiler J, Gough B, Jungman G, Alken P, Booth M, Rossi F. GNU Scientific Library Reference Manual, 3rd edn. ISBN 0954612078: United Kingdom: Network Theory Limited; 2009.

Google Scholar

Novak B, Tyson JJ. Design principles of biochemical oscillators. Nat Rev Mol Cell Biol. 2008; 9(12):981–91.

Article
CAS
PubMed
PubMed Central
Google Scholar

Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. The large-scale organization of metabolic networks. Nature. 2000; 407(6804):651–4.

Article
CAS
PubMed
Google Scholar

Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000; 406(6794):378–82.

Article
CAS
PubMed
Google Scholar